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Pharmacotherapy for Chronic 
Insomnia:  A Brief Survey of 
PCP Attitudes and Preferences
Sorscher AJ1,3*, Siddiqui AA2, Olson A3 and Johnson D4
Abstract
Purpose: To examine primary care professionals’ (PCP) attitudes 
and prescribing preferences toward hypnotic medications to treat 
chronic insomnia.
Methods: An online survey was sent to members of the Dartmouth 
CO-OP, a practice-based primary care research network in Maine, 
Vermont, and New Hampshire.  The survey begins with a case 
vignette of a 64-year old woman suffering from chronic insomnia. 
Clinicians were then presented with eight questions about 
management of the patient and their attitudes toward prescribing 
medications, focusing on benzodiazepines/benzodiazepine 
receptor agonists (BDZ/BZRAs).
Results: 103 of 198 clinicians (52%) responded.  Regarding choice 
of medication for the case vignette, 80% of respondents preferred the 
off-label use of hypnotics such as trazodone or melatonin; 11% stated 
they would choose BDZs and 21% would choose BZRAs.  Strong 
majorities expressed that negative consequences would occur with 
use of BDZ/BZRAs, including tolerance (77%), dependence (68%), 
other side effects (53%), and addiction (51%). PCP preference for 
off- label prescribing was correlated to levels of concern about harms 
(addiction, dependence, tolerance, side effects) of BDZ/BZRAs as 
measured on a global medication risk score in this survey.  In addition, 
14% of respondents felt that pharmacotherapy was not an appropriate 
therapeutic option for chronic insomnia in the case vignette.
Conclusion: Most of the clinicians surveyed acknowledged a 
legitimate role for hypnotic medications in chronic insomnia but 
expressed reservations toward BDZ/BZRAs despite their FDA-
approval and proven efficacy.  There appears to be a gap between 
published guidelines for selection of sedative-hypnotic medications 
and PCP preferences.
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Introduction
Chronic insomnia, defined as difficulty obtaining adequate 
sleep despite making an opportunity for it with resultant negative 
daytime consequences, is a prevalent condition affecting an estimated 
10% of adults in the U.S [1,2]. Because it frequently occurs along 
with other common conditions such as depression, chronic pain, 
and polypharmacy, primary care professionals (PCPs) encounter 
insomnia in even greater frequencies:  it is estimated that 50% of 
people who present to primary care clinics have sleep complaints [3].
Treatment options for insomnia fall in to one of two categories: 
cognitive-behavioral therapies and pharmacotherapy.  Cognitive-
behavioral therapy for insomnia (CBT-I) is highly effective but there 
is a well-documented shortage of trained providers of that therapy 
[4-6].  Because of this, PCPs must frequently decide whether or not to 
offer sleeping pills for the treatment of chronic insomnia [4].
Use of hypnotic medications has increased dramatically in recent 
years:  data from the NHANES (reflecting prescribing patterns in 
ambulatory settings) reveals a 29 % increase in prescriptions for 
hypnotic medications from 1999-2010 [7].  In 2010, there were 60 
million prescriptions for hypnotic medications with sales of over $2 
billion in the U.S [8,9]. While there appears to be an increasing use 
of hypnotic medications by health care professionals, some authors 
on this topic raise concerns about the use of sleeping pills, especially 
benzodiazepines/benzodiazepine agonists citing lack of effectiveness 
and possible side effects such as falls and the potential for addiction, 
tolerance, and dependence [7,10-12].
There has been only one study of provider attitudes toward the 
use of sleeping pills conducted in the U.S., and this was limited in 
scope.  This report consisted of interviews with 33 physicians in the 
Philadelphia area regarding prescriptions of benzodiazepines for 
insomnia in elderly patients [13]. These physicians were generally 
supportive of using benzodiazepines citing their effectiveness 
and downplaying concerns about addiction.  Interestingly, the 
authors of the study interpreted these “accepting” attitudes toward 
benzodiazepines to be evidence that the physicians were practicing 
substandard care and not properly appreciating the hazards of using 
these medications.  
In contrast to the lone report in the U.S., surveys of PCP attitudes 
and prescribing patterns for sleeping pills have been published in 
Europe as well as Canada, Australia, and Thailand.  In general, these 
reports reveal significant ambivalence toward BDZ/BZRAs [14-23].
This study seeks to determine U.S. primary care professionals’ (PCP) 
attitudes and prescribing preferences toward hypnotic medications to 
treat chronic insomnia.  We focus upon benzodiazepines (estazolam, 
temazepam, triazolam, quazepam, flurazepam) and benzodiazepine 
receptor agonists (eszopiclone, zolpidem, and zaleplon) – families 
which comprise most of the hypnotic agents that are FDA-approved 
for the treatment of insomnia.
Methods
Study design
In this survey, we presented a clinical vignette of a middle 
aged woman with chronic insomnia without co-morbid illness 
that  persists despite reasonable attempts to improve sleep hygiene: 
“Ms. D.C. is a 64-year-old woman who presents with a complaint of 
insomnia for the past 12 years, ever since menopause.   She awakens 
“like clockwork” at 3 AM, her mind becomes active, and she can’t 
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fall back to sleep for several hours.  She pays meticulous attention to 
sleep hygiene (no caffeine, no TV in the bedroom, no napping in the 
daytime, etc.).  Despite these measures, she only gets five hours of 
sleep and feels exhausted in the daytime.  Her past medical history 
is negative”.
Participants were then presented with a series of seven statements 
(responses on a 5-point Likert scale) about attitudes and behaviors 
toward prescribing medication for chronic insomnia (Table 1). In 
addition, an eighth statement was presented inquiring about the 
appropriateness of using pharmacotherapy to treat chronic insomnia.
Responses to four questions about attitudes toward BDZ/BZRAs 
(Q1-4) were summed to create a “global medication risk score” 
(range: 4-20), with higher scores representing greater concern about 
addiction, dependence, tolerance, and side effects with BDZ/BZRAs. 
Chi square and student’s t-tests were used to analyze the categorical 
and global variables.
Participants/Procedure:  An invitation to the survey link was sent 
out to members of the Dartmouth CO-OP Practice-based Research 
Network (PBRN).  Membership consists of primary care providers 
in Maine, New Hampshire, and Vermont and includes family 
physicians, internists, and adult nurse practitioners and physician’s 
assistants.  
Survey data were collected and managed using REDCap electronic 
data capture tools hosted at Dartmouth-Hitchcock Medical Center. 
REDCap (Research Electronic Data Capture) is a secure, web-based 
application designed to support data capture for research studies [24].
After the initial invitation, the survey invitation was an iterative 
process for 10 weeks to non-responders. All survey responses were 
collected anonymously unless participants wished to have their name 
entered into a drawing for a $25 gift card. 
The study protocol was approved by the Dartmouth Committee 
for Protection of Human Subjects.
Results
198 clinicians received invitations and 103 completed the survey, 
for a response rate of 52%.   Demographics of the respondents are 
presented in Table 2. 
14% of respondents expressed that sedative-hypnotics are not 
appropriate to manage chronic insomnia (agree/strongly agree).  This 
left 58% who expressed that pharmacotherapy is a reasonable option 
and 26% who were neutral in their opinion on this matter (Q8).  
Regarding choice of medication, 11% “agreed” that 
benzodiazepines were their first line therapy (Q5) and 21% endorsed 
benzodiazepine receptor agonists for initial therapy (Q6).   In 
comparison, a stronger preference was found in favor of off-label use 
of sedating medications (such as trazodone and melatonin) with 80% 
of respondents expressing that they were likely to choose hypnotic 
medications from classes other than BDZ/BZRAs for the patient (Q7).
Strong majorities of respondents expressed that significant risks 
were either “likely” or “very likely” to occur with BDZ/BZRAs.  This 
includes:  tolerance (77%), dependence (68%), side effects (53%) and 
addiction (51%)  (Q1-4).  Concerns about tolerance, dependence, 
and side effects were raised equally regardless of respondents’ age 
group, gender, and specialty.  However, regarding addictive potential, 
we found a significant difference in attitude based upon training 
background: 85% of nurse practitioners and physician’s assistants 
expressed significant concerns about addiction potential, far greater 
than respondents from family practice (43%) and internal medicine 
(38%) (chi-square, p < .001).
Preference for either BDZ or BZRAs was significantly correlated 
with lower “global BDZ/BZRA risk” scores reflecting less overall level 
of concern about tolerance, dependence, addiction, and side effects 
(aggregate of Q1-4).  PCPs who were likely to prescribe BDZs had 
a mean global medication risk score of 12.10 compared to 14.76 
for those who would not prescribe them (p < .002).  Those likely 
to prescribe BZRAs had a mean score of 13.19 compared to 14.82 
for those who would not prescribe them (p < .011).   Conversely, 
respondents who stated they would select non BDZ/BZRAs options 
exhibited significantly higher mean global medication risk scores for 
these medications (14.80 for BDZs; 13.26 for BZRAs, p < .022).   
Discussion
The survey revealed an acceptance that hypnotic medications are 
a legitimate option to treat chronic insomnia with only 14% outright 
rejecting their use in the case vignette. This is in agreement with 
newer thinking about chronic insomnia that recognizes the important 
 * addiction: persistent drug-seeking behavior despite negative consequences
** tolerance: decreased effectiveness after repeated usage
 *** dependence: physiological withdrawal will occur if medication is discontinued
Strongly Disagree Disagree Neutral Agree Strongly Agree
Q1 Benzodiazepines/benzodiazepine agonists are likely to be addictive.* 3/103 (2.9%) 21/103 (20.4%) 25/103 (24.3%) 38/103 (36.8%) 15/103 (14.6%)
Q2 Benzodiazepines/benzodiazepine agonists may work initially, but tolerance will develop.** 0/103 (0%) 6/103 (5.8%) 17/103 (16.5%) 59/103 (57.3%) 20/103 (19.4%)
Q3 Benzodiazepines/benzodiazepine agonists may work, but dependence will develop.*** 1/103 (1%) 14/103 (13.6%) 16/103 (15.6%) 51/103 (49.5%) 19/103 (18.4%)
Q4 Side effects to benzodiazepines/benzodiazepine agonists are likely to occur. 0/103 (0%) 20/103 (19.4%) 27/103 (26.2%) 46/103 (44.7%) 8/103 (7.8%)
Q5 I am likely to use benzodiazepines (e.g. temazepam) for this patient. 31/103 (30.1%) 47/103 (45.6%) 11/103 (10.7%) 11/103 (10.7%) 0/103 (0%)
Q6 I am likely to use a benzodiazepine agonist (e.g. zolpidem) for this patient 20/103 (19.4%) 38/103 (36.9%) 22/103 (21.4%) 22/103 (21.4%) 0/103 (0%)
Q7 I am likely to prescribe a different type of sleeping medication (melatonin, trazodone, etc.) for this patient. 2/103 (1.9%) 9/103 (8.7%) 8/103 (7.7%) 55/103 (53.4%) 27/103 (26.2%)
Q8 Prescribing sleeping pills is inappropriate – the patient needs to address her insomnia. 14/103 (13.6%) 46/103 (44.7%) 27/103 (26.2%) 11/103 (10.7%) 3/103 (2.9%)
Table 1: Participant Responses to Survey Questions.
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contribution of inherent “hyperarousal” physiology to this condition. 
Whereas in the past, expert opinion held that insomnia was always 
the result of some underlying condition that, if addressed, would 
cure the sleep complaint it is now understood that in many cases, 
chronic insomnia can occur without an underlying cause and may 
need specific treatment with either cognitive-behavioral techniques 
or pharmacotherapy [25].
Regarding the specific choice of pharmacotherpeutic agent, 
respondents in this survey expressed substantial reservations toward 
BDZ/BZRAs.   Similar levels of distrust of BDZ/BZRAs are found in 
the European reports on this topic [19]. The present survey also found 
twice as many practitioners willing to prescribe BZRAs compared to 
BDZs.  This is similar to a preference for BZRAs (compared to BDZs) 
found in European reports such as from Germany and the United 
Kingdom [16,19]
We found that antipathy toward BDZ/BZRAs and the tendency 
to recommend off-label use of other sedating medications was 
associated with concerns about dependence, side effects, addiction, 
and, especially tolerance.  Some of these attitudes are not borne out 
by the scientific literature.  For example, studies of eszopiclone and 
zolpidem have both indicated that tolerance is unlikely, at least over 
1 year of nightly usage [26,27]. Other reports indicate that rates of 
dependence are only 10-30% in chronic benzodiazepine users. 
And although BDZs are well known to have an addictive potential, 
reports such as that by Mahowald and Schenck indicate that the 
rates of  addiction are very low in people with no prior history of 
substance abuse. As one consensus conference of experts in insomnia 
concluded:  “Insomniacs tend to show therapy-seeking,rather than 
drug-seeking behavior, and patients without histories of drug abuse 
are unlikely to self-escalate dosage of currently available hypnotics 
[28-30].
PCPs from all specialties in this survey strongly preferred off-
label use of medications such as trazodone and melatonin compared 
to BDZ/BZRAs.    Of concern, neither of these choices has as strong 
an evidence base to support their use as BDZ/BZRAs.  Furthermore, 
trazodone often engenders side effects due to its anticholinergic 
activity.  As for melatonin, data to support its effectiveness, proper 
dose, and even purity is in question.  This viewpoint is expressed in 
the Medical Letter summary of pharmacotherapy for insomnia [31]
There are some limitations to this exploratory survey, such as the 
sample size and limited geographic reach (northern New England 
providers).  The findings in this survey need to be repeated in larger 
populations of PCPs with greater geographic variation in the U.S. in 
order to determine how commonly held these attitudes are.  Also, 
the survey is based upon a single vignette, that of a middle-aged 
woman with chronic insomnia without other stated comorbidities. 
No doubt, responses would vary depending upon the presence of 
other co morbidities such as chronic pain, mental health disorders, 
or substance abuse that frequently co-occur with insomnia. 
Additionally, for brevity, the survey used “trazodone and melatonin" 
to stand broadly for all non BDZ/BDZA choices and thereby did not 
allow for analysis to compare these and other agents that are sedating 
but used less frequently such as ramelteon, doxepin, and atypical 
antipsychotics.  In defense of this, we note that amongst prescription 
hypnotics, trazodone is far more widely prescribed than any of the 
non BDZ/BZRA choices just cited and melatonin, available without 
prescription, is used even more commonly than trazodone [7,32].
While cognitive-behavioral therapy remains the preferred 
initial treatment for chronic insomnia, [6] there has been growing 
acceptance from expert panels and consensus conferences for the 
use of pharmacotherapeutic agents to treat this disorder [30,33]. 
This survey reveals that PCPs are increasingly willing to use 
pharmacotherapy for chronic insomnia but frequently choose off-
label use of sedating antidepressants such as trazodone and other non 
FDA approved medications such as melatonin.  We found that these 
preferences are driven by concerns about addiction, dependence, 
tolerance, and side effects from BDZ/BZRA medications.  These 
views stand in contrast to treatment guidelines from the American 
Academy of Sleep Medicine and the Medical Letter that propose BDZ 
and BZRAs, as first line treatments for chronic insomnia [31,34].
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